--- canonical_name: sh-Polypeptide-59 alternate_names: Synthetic Human Platelet-Derived Growth Factor B, PDGF-B, PDGF-BB, Recombinant Human PDGF-BB, rh-PDGF canonical_topic: sh-Polypeptide-59 for Hair Regrowth short_topic_lc: sh_polypeptide_59_hair creation_date: 2026-0708-1916 creator_ai_fullname: Opus 4.8 ep_keywords: Growth Factor Peptides, Cosmetic Peptides, Topical Peptides --- # sh-Polypeptide-59 for Hair Regrowth
Evidence Review created on 07/08/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Synthetic Human Platelet-Derived Growth Factor B, PDGF-B, PDGF-BB, Recombinant Human PDGF-BB, rh-PDGF ## Motivation sh-Polypeptide-59 is a laboratory-made copy of a natural human signaling protein called platelet-derived growth factor B. It is produced by fermentation in engineered bacteria and belongs to a growing family of "growth factor" ingredients added to leave-on hair serums that aim to wake dormant follicles and thicken thinning hair. The parent protein helps regulate the specialized cells at the base of each hair follicle and supports the follicle's active growing phase. Interest in it for hair grew alongside the popularity of platelet-rich scalp treatments, which are naturally rich in the same protein and which some clinicians use to nudge resting follicles back into growth. Cosmetic formulators responded by adding the isolated protein directly to serums, often paired with tiny needling devices meant to help it reach its target. This review examines the evidence for and against applying sh-Polypeptide-59 to the scalp for hair regrowth. It looks at how the protein is thought to work, how strong the human data actually are, the potential risks, and how the ingredient is typically used, so the picture can be weighed against more established hair options. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level, expert-driven overviews of hair-loss biology and the growth-factor approach that provide context for evaluating sh-Polypeptide-59. * [The Science of Healthy Hair, Hair Loss and How to Regrow Hair](https://www.hubermanlab.com/episode/the-science-of-healthy-hair-hair-loss-and-how-to-regrow-hair) - Andrew Huberman A structured tour of hair biology and the mechanisms behind common treatments, including the central role of follicle stem cells and blood flow that growth-factor serums such as sh-Polypeptide-59 are designed to target. It is useful for placing an unproven ingredient beside established options like minoxidil, finasteride, microneedling, and platelet-rich plasma (PRP). * [AMA #63: A Guide for Hair Loss: Causes, Treatments, Transplants, and Sex-Specific Considerations](https://peterattiamd.com/ama63/) - Peter Attia A practical clinician's overview of androgenetic alopecia (male- or female-pattern hair loss) and its treatment ladder, including where platelet-rich plasma and other regenerative options fit and how much data actually support them. It frames the realistic expectations and cost trade-offs against which a cosmetic growth-factor serum should be judged. * [Support Hair and Scalp Regeneration](https://www.lifeextension.com/magazine/2014/6/support-healthy-hair-and-scalp-regeneration) - Goldfaden & Goldfaden A consumer-facing article centered on the same follicle dermal stem cells that platelet-derived growth factor acts on, describing how activating these cells can drive hair formation. It illustrates the mechanistic logic behind topical "regeneration" products while relying largely on early-stage and preliminary evidence. * [Platelet-derived growth factor signaling modulates adult hair follicle dermal stem cell maintenance and self-renewal](https://pubmed.ncbi.nlm.nih.gov/29302347/) - González et al., 2017 A primary study showing that platelet-derived growth factor signaling is required to maintain and expand the dermal stem cells that repopulate the follicle and that its ligand improves their ability to induce new follicles. It is the closest direct mechanistic support for why this specific protein might matter to hair, albeit in mice and isolated cells rather than human scalp. * [Role of platelet-derived growth factors in physiology and medicine](https://pubmed.ncbi.nlm.nih.gov/18483217/) - Andrae et al., 2008 An authoritative narrative review of the entire platelet-derived growth factor family, its receptors, and its roles in development, tissue repair, and disease. It is valuable both for understanding the intended biology and for appreciating the protein's documented involvement in fibrosis and tumor stroma, which underpins the safety questions raised later in this review. Note: Among the prioritized experts, substantial coverage was found for Andrew Huberman, Peter Attia, and Life Extension; Rhonda Patrick's and Chris Kresser's platforms did not contain material specific to growth factors for hair regrowth at the time of writing. ## Grokipedia No dedicated Grokipedia article exists for sh-Polypeptide-59. ## Examine No dedicated Examine article exists for sh-Polypeptide-59. Examine.com focuses on ingestible supplements and does not cover topical cosmetic growth-factor ingredients such as this one. ## ConsumerLab No dedicated ConsumerLab article exists for sh-Polypeptide-59. ConsumerLab tests ingestible supplements and does not cover topical cosmetic growth-factor ingredients. ## Systematic Reviews No systematic reviews or meta-analyses for sh-Polypeptide-59 were found on PubMed as of July 8, 2026. ## Mechanism of Action sh-Polypeptide-59 is the cosmetic-nomenclature name (under the International Nomenclature of Cosmetic Ingredients, or INCI) for a recombinant, single-chain copy of the B subunit of platelet-derived growth factor (PDGF), made by bacterial fermentation. In the body, two B subunits pair to form the active protein PDGF-BB, a member of a family of signaling proteins that direct the growth and movement of connective-tissue and blood-vessel cells. * **Receptor signaling:** PDGF-BB binds PDGF receptors (PDGFR-α and PDGFR-β) on the surface of target cells. These receptors are receptor tyrosine kinases — enzymes that, once switched on, add phosphate tags to themselves and trigger internal cascades. The main downstream routes are the PI3K/Akt pathway (a cell-survival and growth signal), the MAPK/ERK pathway (a proliferation signal), and phospholipase C-gamma (a lipid-signaling enzyme that helps relay the receptor's message inside the cell). The net effect is to make certain cells divide, survive, and migrate. * **Relevance to the hair follicle:** The follicle grows through a repeating cycle — anagen (active growth), catagen (regression), and telogen (rest). Its behavior is directed by the dermal papilla, a small cluster of cells at the base of the follicle. Platelet-derived growth factor helps maintain the dermal stem cells that rebuild the papilla, promotes proliferation of dermal papilla cells, and is thought to help push resting follicles into the growth phase. It also encourages angiogenesis (new small-blood-vessel formation), which improves the follicle's blood supply. * **Why it appears in hair products:** The same protein is a major component released by platelets, which is why platelet-rich plasma (PRP) — concentrated from a person's own blood — delivers it to the scalp. Cosmetic serums instead supply the isolated recombinant protein, frequently alongside other recombinant growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor 1 (IGF-1), and basic fibroblast growth factor (bFGF). * **Competing mechanistic views:** Supporters argue the follicle biology above justifies topical use, especially when penetration is enhanced by microneedling. Skeptics counter that PDGF-BB is a large protein — its active form is roughly 25 kilodaltons (kDa, a unit of molecular weight), far above the approximately 500-dalton limit usually cited for passive absorption through intact skin — so it may never reach the dermal papilla without a delivery aid. The same proliferative signaling is also a double-edged feature: platelet-derived growth factor is a recognized driver of fibrosis (scar-like tissue) and of the supportive tissue around some tumors, so its actions are not uniformly desirable. **Pharmacological properties:** sh-Polypeptide-59 is a protein, not a small molecule. It is therefore not metabolized by liver CYP (cytochrome P450) enzymes; instead it is broken down by proteases (protein-cleaving enzymes) in tissue. Its circulating half-life as a free protein is very short (on the order of minutes), and any systemic exposure from correct topical use is expected to be minimal. Its target selectivity is for the PDGF receptors, and its tissue distribution after topical application is intended to be local to the scalp. ## Historical Context & Evolution * **Original purpose:** Platelet-derived growth factor was first identified as the component of serum that stimulates fibroblasts and smooth-muscle cells to divide during wound repair. Its recombinant B-subunit form, becaplermin, was developed as a wound-healing therapy and approved by the U.S. Food and Drug Administration (FDA) in 1997 as a topical gel (marketed as Regranex) for diabetic foot ulcers — not for hair. * **Route into hair care:** The move toward hair began indirectly. Clinicians using platelet-rich plasma — which is naturally rich in platelet-derived growth factor — reported improvements in some patients with pattern hair loss, and aesthetic dermatology adopted recombinant growth-factor cocktails first for skin rejuvenation and then for the scalp. As these ingredients entered consumer cosmetics, the standardized INCI name "sh-Polypeptide-59" was assigned to the recombinant PDGF-B protein. * **What the historical wound-healing evidence actually showed:** In its approved wound use, topical recombinant PDGF-BB modestly improved ulcer closure. A later safety question arose when a matched cohort study found more cancer deaths among heavy users of the wound gel (three or more tubes). This prompted an FDA boxed warning in 2008. * **How the picture was reassessed:** Rather than being simply "debunked," the safety signal was re-examined with longer follow-up and additional post-marketing studies, which did not confirm an overall increase in cancer or cancer death. On that basis, the FDA removed the boxed warning in 2018. Both the initial signal and its later softening are described in the Risks section so the reader can weigh the current standing directly. * **Evolution of opinion:** Early caution about the mitogenic (cell-division-promoting) nature of growth factors has eased somewhat as reassuring wound-care data accumulated, but this history is specific to an open-wound, high-dose setting and does not by itself establish that a low-dose cosmetic scalp serum is either effective or safe. ## Expected Benefits Benefits are framed for a proactive, health-focused adult evaluating an early-stage cosmetic option rather than as population-level outcomes. Because no controlled human study has tested topical sh-Polypeptide-59 for hair, no benefit rises above "Low," and most are "Speculative." ### Low 🟩 #### Support of Dermal Papilla and Hair Follicle Stem Cell Activity The most defensible benefit is biological rather than cosmetic: platelet-derived growth factor helps maintain and activate the dermal stem cells and dermal papilla cells that drive follicle regeneration and the growth phase. This is supported by mouse genetic studies and isolated-cell experiments in which the protein sustained stem-cell self-renewal and improved the cells' capacity to induce new follicles. The evidence is preclinical, and whether a topically applied protein of this size actually reaches these cells in human scalp is unproven, so any real-world benefit remains inferential. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Increased Hair Density and Thickness The headline consumer claim — visibly fuller, thicker hair — has no isolated-ingredient trial behind it. The basis is analogy to platelet-rich plasma and to multi-ingredient growth-factor serums, which have shown modest density gains in small studies but always as mixtures, so the specific contribution of sh-Polypeptide-59 cannot be separated out. #### Prolongation of the Anagen (Growth) Phase By acting on the dermal papilla, the protein is proposed to lengthen the active growth phase and delay the shift to resting, which would reduce shedding and support longer, thicker shafts. This rests on mechanistic and animal data rather than on human scalp measurements. #### Improved Perifollicular Blood Supply Platelet-derived growth factor recruits the support cells of blood vessels and promotes new-vessel formation, which could improve the blood supply feeding each follicle — a plausible contributor to hair growth. No human study has demonstrated this effect from the topical cosmetic ingredient. #### Enhanced Results When Combined with Microneedling or Minoxidil Because microneedling creates transient channels that could let a large protein penetrate, and because minoxidil independently promotes growth, sh-Polypeptide-59 is often positioned as an add-on. Any synergy is currently a reasonable hypothesis rather than a demonstrated outcome for this ingredient. ## Benefit-Modifying Factors * **Degree of androgen-driven miniaturization:** In pattern hair loss the follicle shrinks under the influence of dihydrotestosterone (DHT, the androgen that miniaturizes genetically sensitive follicles). A growth-factor push may be overridden by ongoing DHT signaling, so any benefit is likely greater when the underlying androgen driver is also addressed. * **Baseline follicle viability:** The protein can only act on follicles that still exist. Miniaturized-but-living follicles are more plausible responders than long-dormant zones or scarred (fibrosed) bald areas where follicles are gone. * **Baseline biomarker status:** Low iron (ferritin), low vitamin D, thyroid dysfunction, or active scalp inflammation can independently cap any hair-growth response, blunting the apparent effect. * **Sex-based differences:** Male- and female-pattern hair loss differ in distribution and hormonal context, and women and men may respond differently; however, no sex-specific data exist for this ingredient. * **Genetic variation in signaling:** Variants affecting the androgen receptor or the platelet-derived growth factor receptors could, in theory, modify how strongly a follicle responds, though this has not been studied for topical use. * **Age:** The dermal stem-cell pool and regenerative capacity decline with age, so older users — including those at the upper end of a health-focused adult audience — may see less response than younger users. ## Potential Risks & Side Effects Risks are framed for a proactive adult applying a cosmetic serum to the scalp. Because the isolated ingredient has no dedicated safety trials in hair, most concerns are theoretical or extrapolated from the same molecule in its wound-care form. ### Low 🟥 #### Local Skin Irritation and Contact Dermatitis The most common realistic issue is local intolerance — redness, itching, stinging, or small bumps (folliculitis) — driven by the serum's preservatives, carrier, the protein itself, or accompanying actives. Reactions are usually mild and reversible on stopping. Enhanced-penetration methods such as microneedling can increase both absorption and irritation. **Magnitude:** Broadly comparable to other leave-on cosmetic scalp serums; reactions are typically mild and resolve on discontinuation. #### Documented Malignancy-Mortality Signal from the Same Molecule ⚠️ Conflicted The identical recombinant protein, sold as a wound gel, was linked in one matched cohort study to more cancer deaths among heavy users (three or more tubes), which led to an FDA boxed warning in 2008. This is the strongest safety signal that exists for the molecule, but it is genuinely conflicted: extended follow-up in the same and later studies found no overall increase in cancer or cancer death, and the warning was removed in 2018. The setting also differs sharply from cosmetic use — open ulcers, high cumulative doses, and an older, sicker population — so the relevance to low-dose intact-skin scalp use is uncertain but cannot be dismissed. **Magnitude:** Up to roughly a 5-fold higher cancer-mortality rate was reported among the heaviest wound-gel users in one cohort; extended follow-up showed no overall increase (hazard ratio — a measure comparing the risk between groups, where 1.0 means no difference — near 1.0–1.2). ### Speculative 🟨 #### Fibrosis or Excess Scar-Tissue Formation Platelet-derived growth factor is a recognized driver of fibroblast proliferation and fibrosis in several diseases. Chronic scalp application could in theory promote unwanted connective-tissue changes, though no such reports exist for the cosmetic ingredient and normal topical exposure is far lower than in disease states. #### Immunogenicity to a Recombinant Protein As a bacterially produced human protein, sh-Polypeptide-59 could in principle provoke a local immune or allergic response, and residual bacterial endotoxin from manufacturing could contribute to irritation. The risk from intact-skin topical use is expected to be low but has not been formally characterized. #### Stimulation of Pre-Existing Skin Lesions Because the protein promotes cell division and blood-vessel growth, there is a theoretical concern that applying it over sun-damaged skin, actinic keratoses (rough, scaly precancerous patches caused by long-term sun exposure), or undiagnosed skin cancers in the treatment field could encourage their growth — a concern amplified if penetration is increased by needling. #### Infection or Folliculitis with Microneedle-Assisted Delivery When paired with microneedling, the barrier is breached, so poor hygiene, unclean devices, or contaminated product can introduce infection or worsen folliculitis. This is a procedure-related risk rather than a property of the protein itself. ## Risk-Modifying Factors * **Personal or family history of skin cancer:** A history of skin cancer, actinic keratoses, or other pre-malignant lesions in the treatment field raises the theoretical concern about stimulating unwanted growth and warrants clinician review before use. * **Baseline skin and scalp condition:** Active scalp infection, inflammatory scalp disease, or broken skin increases the chance of irritation, infection, and greater-than-intended absorption. * **Baseline biomarkers:** Unlike their influence on the likelihood of benefit, no routine blood biomarker (e.g., ferritin, vitamin D, or thyroid markers) meaningfully changes the local risk profile of a minimally absorbed topical serum; such labs bear on interpreting response rather than on predicting harm. * **Sex and hormonal state:** No sex-specific safety data exist. Pregnancy and breastfeeding are a separate precaution given the complete absence of safety data for a growth-factor protein during these periods. * **Age:** Older skin is more likely to harbor undiagnosed sun-damaged or pre-malignant lesions, which is the population subgroup in whom the theoretical proliferation concern is most relevant. * **Genetic variation in growth-factor signaling:** Variants in the platelet-derived growth factor receptor pathway could in principle alter tissue sensitivity, but no clinically actionable data exist for topical cosmetic use. ## Key Interactions & Contraindications * **Topical minoxidil (over-the-counter):** Additive by design — both aim to promote growth. Severity: generally safe combination; the main consequence is additive scalp irritation. Mitigation: introduce one product at a time and separate application times if irritation appears. * **Topical retinoids (tretinoin, adapalene) and chemical exfoliants (salicylic acid, glycolic acid):** These thin or disrupt the outer skin barrier and can increase both penetration and irritation of the serum. Severity: caution. Consequence: dermatitis, stinging, unpredictable absorption. Mitigation: separate application by hours or days and reduce frequency if irritation occurs. * **Topical corticosteroids:** May blunt local growth-factor and inflammatory signaling. Severity: caution (possible reduced effect). Mitigation: separate use in time; discuss with a clinician if a steroid is medically needed. * **Microneedling, low-level laser therapy, and platelet-rich plasma:** Additive or potentiating combinations frequently marketed together; all increase delivery or growth signaling. Severity: caution. Consequence: greater irritation and, with needling, infection risk. Mitigation: sterile technique, conservative needle depth, and staged introduction. * **Other recombinant growth-factor or peptide serums:** Additive growth-factor exposure. Severity: caution. Consequence: cumulative stimulation and irritation. Mitigation: avoid stacking multiple undocumented growth-factor products simultaneously. * **Populations who should avoid it:** People who are pregnant or breastfeeding (no safety data); anyone with a personal history of scalp or skin cancer, or with actinic keratoses or other pre-malignant lesions in the treatment field; those with active scalp infection (for example, tinea capitis or bacterial folliculitis) or active inflammatory scalp disease; and anyone with known hypersensitivity to the product. Severity for these groups: relative contraindication (avoid or use only under clinician supervision) because the consequence — from unknown developmental risk to potential stimulation of abnormal tissue or worsened infection — outweighs the unproven cosmetic benefit. ## Risk Mitigation Strategies * **Patch testing before full use:** A patch test — a small amount applied to a discreet area for 48–72 hours and observed for redness, itching, or bumps before whole-scalp use — reduces the risk of a widespread contact-dermatitis reaction. * **Screening the treatment field for skin lesions:** A clinician evaluation of suspicious spots, actinic keratoses, or non-healing lesions before starting, with the serum kept away from those areas, addresses the theoretical concern that a growth-promoting protein could stimulate pre-malignant or malignant tissue. * **Sterile, conservative microneedling technique:** Disinfecting the device, keeping home needle depth at or below roughly 0.5–1.0 mm, following label timing, and avoiding needling over broken or infected skin together mitigate infection, folliculitis, and greater-than-intended penetration. * **Modest cumulative exposure:** Staying within the manufacturer's small-volume directions rather than heavy off-label dosing serves as a deliberate hedge against the malignancy-mortality signal seen with high cumulative doses of the same protein in wound care. * **Avoidance during pregnancy and breastfeeding:** Withholding the serum until safety data exist is a precaution grounded in the unknown effects of a growth-factor protein during these periods and the unproven benefit. * **Discontinuation on any persistent reaction:** Stopping the serum and seeking evaluation when irritation, spreading redness, or new lesions appear limits progression of both dermatitis and infection. ## Therapeutic Protocol There is no standardized medical protocol, because sh-Polypeptide-59 is a cosmetic ingredient rather than an approved hair drug. The patterns below reflect how growth-factor serums are typically used in aesthetic practice and by informed consumers. * **Typical formulation and concentration:** sh-Polypeptide-59 usually appears as one of several recombinant growth factors in a leave-on serum; exact concentrations are rarely disclosed on cosmetic labels, which is a key transparency limitation. * **Application routine:** Serums are commonly applied once or twice daily to a clean, dry scalp, or on a 1–2 times per week schedule when paired with in-clinic microneedling or mesotherapy delivery. * **Competing approaches (presented without a default):** The main alternatives are (a) daily leave-on serum for at-home use, (b) in-clinic microneedle or mesotherapy delivery to improve penetration, and (c) platelet-rich plasma, which supplies the same growth factor from the user's own blood. Each has different cost, invasiveness, and evidence profiles, and none is clearly established as superior for this ingredient. * **Practitioners and products that popularized the approach:** Growth-factor cosmetic lines used in dermatology practices (for example, AnteAGE and Calecim, named only as representative products, not endorsements) helped popularize topical growth-factor serums, while platelet-rich plasma was popularized within hair-restoration clinics. * **Best time of day:** No chronobiology data exist; timing is chosen for routine adherence rather than for any demonstrated advantage. * **Half-life and dosing frequency:** Because the free protein has a very short half-life and limited local residence, repeated application (daily or per-session) is the norm; there is no depot effect that would justify infrequent dosing. * **Single versus split dosing:** Use is effectively split across the day (once or twice daily) rather than a single large application, consistent with the short residence time. * **Genetic considerations:** Response is expected to depend more on androgen-receptor and DHT sensitivity than on the serum itself; platelet-derived growth factor receptor variants are of theoretical interest only. * **Sex-based considerations:** Protocols are not sex-specific, though the underlying pattern-hair-loss context differs between men and women and should shape expectations. * **Age considerations:** Older users may need longer, more consistent use for any effect and should be more vigilant about screening the scalp for sun-damaged skin. * **Baseline biomarker considerations:** Correcting iron, vitamin D, and thyroid status before or alongside use gives any growth-factor effect the best chance to show. * **Pre-existing conditions:** Underlying scarring alopecia, active scalp disease, or nutritional deficiency should be addressed first, as they will otherwise limit response. ## Discontinuation & Cycling * **Lifelong versus short-term:** Like other topical hair actives, any benefit depends on continued use; the ingredient does not "cure" hair loss, and gains would be expected to fade over subsequent hair cycles once it is stopped. * **Withdrawal effects:** There is no pharmacological dependence or withdrawal syndrome. The main consequence of stopping is a gradual return toward the untreated baseline, including any shedding that treatment had slowed. * **Tapering:** No taper is needed; the product can be stopped abruptly without a rebound beyond loss of any accrued benefit. * **Cycling:** There is no evidence that cycling on and off preserves or enhances efficacy. Some users pair intermittent microneedling sessions with continuous serum use, but this is a delivery choice rather than a validated cycling strategy. ## Sourcing and Quality * **Protein stability and packaging:** Recombinant proteins degrade with heat, light, and time. Prefer products in opaque, airless, or single-use packaging, and note whether the manufacturer recommends refrigeration; serums stored improperly may contain little active protein. * **Concentration and source transparency:** Most cosmetics do not disclose how much sh-Polypeptide-59 they contain. Favor brands that state the amount and the recombinant source, since ingredient-list presence alone says nothing about a meaningful dose. * **Manufacturing and purity testing:** Because the protein is produced in engineered *E. coli*, endotoxin (a bacterial contaminant) is a relevant quality concern. Look for manufacturers that reference good manufacturing practices and endotoxin or purity testing. * **Reputable brands and compounding:** Established aesthetic growth-factor lines and reputable compounding sources are preferable to anonymous marketplace sellers. Be skeptical of products that make drug-level regrowth claims, which are not permitted for a cosmetic. * **Realistic labeling:** Prefer products that describe the ingredient's status honestly (a cosmetic with mechanistic rationale) over those implying proven, drug-equivalent results. ## Practical Considerations * **Time to effect:** Hair cycles are slow. Even under optimistic assumptions, no visible change should be expected before about 3–6 months of consistent use, mirroring the timeline of established hair actives. * **Common pitfalls:** Expecting drug-level regrowth from a cosmetic; stopping before the minimum evaluation window; using the serum as a standalone rather than alongside proven approaches; and ignoring the underlying androgen driver of pattern hair loss. * **Regulatory status:** sh-Polypeptide-59 is marketed as a cosmetic ingredient, not an FDA-approved drug for hair, so hair-regrowth claims are unapproved. The identical protein is FDA-approved as a drug only in a wound-healing gel, and that approval does not extend to scalp or hair use. * **Cost and accessibility:** Growth-factor serums are relatively expensive compared with generic minoxidil and are sold widely online without prescription; the cost-to-evidence ratio is unfavorable relative to established options. ## Interaction with Foundational Habits * **Sleep:** Direction — indirect/none. A topical serum is not expected to affect sleep, and there is no evidence it should be timed around sleep. Adequate sleep supports normal hormonal regulation of the hair cycle, so good sleep is complementary background support rather than a direct interaction. * **Nutrition:** Direction — indirect, potentially potentiating. Follicle response to any growth signal depends on adequate protein, iron, vitamin D, and zinc; deficiencies can cap results. Practically, correcting these through diet or targeted repletion gives a growth-factor serum its best chance, whereas crash dieting can trigger shedding that masks benefit. * **Exercise:** Direction — indirect. Regular activity improves overall circulation and may modestly support scalp perfusion, aligning loosely with the protein's blood-vessel-promoting mechanism. There is no need to time application around workouts; applying after washing off sweat is the only practical consideration. * **Stress management:** Direction — indirect. Chronic stress can push follicles into resting and shedding (telogen effluvium), which would blunt or obscure any benefit, plausibly via cortisol effects on the hair cycle. Managing stress helps keep more follicles in the growth phase where a growth-factor serum could act. ## Monitoring Protocol & Defining Success Because sh-Polypeptide-59 is a topical cosmetic with minimal systemic exposure, monitoring focuses less on safety labs and more on ruling out treatable causes of hair loss at baseline and on tracking hair objectively over time. Before starting, a baseline workup is worthwhile to identify contributors to hair loss that would otherwise limit or mimic a response, and to document the starting point with standardized photographs and, ideally, a clinician's assessment. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | Ferritin (iron stores) | 40–70 ng/mL | Low iron stores are a common, correctable cause of hair shedding | Conventional labs often flag "low" only below ~15–30 ng/mL; the functional target for hair is higher. Draw when not acutely ill, as ferritin rises with inflammation | | Vitamin D (25-hydroxyvitamin D) | 40–60 ng/mL | Deficiency is linked to hair-cycle disruption | Conventional "sufficient" starts at 30 ng/mL; no fasting required | | TSH | 0.5–2.5 mIU/L | Thyroid dysfunction is a reversible driver of diffuse hair loss | TSH (thyroid-stimulating hormone). Best paired with free T4 (thyroxine) if abnormal; morning draw preferred as TSH varies through the day | | Total and free testosterone | Sex- and age-specific reference | Provides hormonal context for pattern hair loss | Morning, fasting sample; interpret alongside symptoms rather than in isolation | | Zinc | 90–120 µg/dL | Deficiency can contribute to shedding and poor follicle function | Take fasting and avoid zinc supplements immediately before testing | | Complete blood count (hemoglobin) | Mid-normal for sex | Screens for anemia that can worsen hair loss | Routine panel; pairs naturally with ferritin | Ongoing monitoring is primarily visual rather than laboratory-based. A reasonable cadence is a baseline set of standardized photographs, then reassessment at about 3 months and 6 months, and every 6–12 months thereafter, since hair changes slowly and short-term judgments are unreliable. Qualitative and self-tracked markers of success include: * Hair density and part width compared with baseline photos taken in consistent lighting * Daily or weekly shedding counts (for example, hairs in the shower or on the pillow) * A gentle hair-pull test trend over time * Subjective texture, coverage, and styling ease * Absence of scalp irritation, new lesions, or signs of infection during use ## Emerging Research Research relevant to sh-Polypeptide-59 is framed here for a proactive reader who wants to know both what could validate the ingredient and what could undercut it. Importantly, no registered clinical trial evaluates topical sh-Polypeptide-59 as an isolated ingredient for hair; the closest evidence comes from peptide- and growth-factor serum trials and from safety data on the same molecule in wound care. * **Peptide growth-factor serum versus minoxidil:** [VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia](https://clinicaltrials.gov/study/NCT07536100) is a recruiting randomized study of about 80 participants comparing a peptide growth-factor serum head-to-head with standard minoxidil — the nearest analog to how sh-Polypeptide-59 would be used, and a design that could strengthen or weaken the case for topical growth factors. * **Growth factors combined with laser:** [Thulium Laser and Growth Factors for Androgenetic Alopecia](https://clinicaltrials.gov/study/NCT07079657) is a recruiting study of roughly 30 participants testing whether combining topical growth factors with laser treatment improves outcomes, relevant to the enhanced-delivery strategy often paired with these serums. * **Growth-factor serum in a different hair-loss setting:** [Keratinocyte Growth Factor Hair Serum for the Prevention of Chemotherapy-Induced Alopecia](https://clinicaltrials.gov/study/NCT04554732) is a completed early-phase study of about 28 participants applying a topical growth-factor serum, offering indirect insight into tolerability and delivery of this class. * **Delivery and penetration science:** A central open question is whether a protein as large as PDGF-BB can reach the dermal papilla through intact skin at all. Future work on microneedle arrays, nanocarriers, and other delivery systems could determine whether the ingredient is even bioavailable topically — a line of research that could strengthen or fatally weaken the concept. * **Long-term safety re-evaluation:** The malignancy question for recombinant PDGF-BB remains the key safety uncertainty. The matched cohort analysis [A matched cohort study of the risk of cancer in users of becaplermin](https://pubmed.ncbi.nlm.nih.gov/21173589/) (Ziyadeh et al., 2011) is the most directly relevant human safety dataset and illustrates how additional follow-up shifted the signal; comparable long-term data for cosmetic scalp use do not yet exist. ## Conclusion sh-Polypeptide-59 is a lab-made copy of a natural human growth-factor protein, added to leave-on scalp serums with the goal of reviving thinning hair. Its rationale is biologically reasonable: the parent protein helps sustain the cells at the base of each follicle, supports the follicle's growing phase, and encourages the small blood vessels that feed it. Laboratory and animal work supports these roles, and the same protein is a natural ingredient of platelet-rich scalp treatments that some clinicians find helpful. What is missing is direct human testing of the ingredient itself. No controlled study has shown that applying sh-Polypeptide-59 to the scalp regrows hair, and it is unclear whether a protein this large can even reach its target through intact skin without needling. The main practical concerns are minor skin irritation and a theoretical, unresolved question about whether growth-factor proteins could encourage unwanted cell growth — a question raised, then largely eased, when the same protein was studied as a prescription wound treatment. Overall, the evidence base is thin and mostly indirect, weighted toward mechanism and analogy rather than results in people seeking hair regrowth. It is best understood as an unproven, early-stage cosmetic option rather than an established treatment, and its true value for hair remains genuinely uncertain. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**